Vbi Vaccines Inc Revenue Growth Rates (VBIV), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Vbi Vaccines Inc  (NASDAQ: VBIV)
 

VBIV's Revenue Growth by Quarter and Year

Vbi Vaccines Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

VBIV Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 1.21
FY 1.21

VBIVs Annual Revenue
Vbi Vaccines Inc's Revenue in the fiscal year 2023 $ 8.68 millions
Vbi Vaccines Inc's Revenue in the fiscal year 2022 $ 1.08 millions
Vbi Vaccines Inc's Revenue in the fiscal year 2021 $ 0.63 millions
Vbi Vaccines Inc's Revenue in the fiscal year 2020 $ 1.06 millions
Vbi Vaccines Inc's Revenue in the fiscal year 2019 $ 2.22 millions




VBIV Revenue first quarter 2024 Y/Y Growth Comment
Vbi Vaccines Inc reported Revenue surge of 147.76% year on year in the first quarter 2024, to $ 1.21 millions, this is lower than Vbi Vaccines Inc's recent average Revenue surge of 160.4%.

Looking into first quarter 2024 results within Major Pharmaceutical Preparations industry 36 other companies have achieved higher Revenue growth. While Vbi Vaccines Inc' s Revenue doubling of 147.76% ranks overall at the positon no. 158 in the first quarter 2024.


VBIV Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December - 193.1 % 262.5 % -50 %
3rd Quarter September - 1968.75 % 190.91 % -63.33 %
2nd Quarter June - 105.71 % 150 % -22.22 %
1st Quarter March 147.76 % 276.92 % -56.67 % -28.57 %
FY   - 696.33 % 73.02 % -

Financial Statements
Vbi Vaccines Inc's first quarter 2024 Revenue $ 1.21 millions VBIV's Income Statement
Vbi Vaccines Inc's first quarter 2023 Revenue $ 0.49 millions Quarterly VBIV's Income Statement


VBIV Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - -87.16 % -9.38 % -27.27 %
3rd Quarter September - 819.44 % -8.57 % -21.43 %
2nd Quarter June - 46.94 % 169.23 % -53.33 %
1st Quarter March 42.82 % 68.97 % 62.5 % 87.5 %
FY (Year on Year)   - 696.33 % 73.02 % -


Back to VBIV Growth rate Comparisons >> Back to VBIV Growth rate Comparisons >>


Revenue first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #37
Healthcare Sector #59
Overall #158

Revenue Y/Y Growth Statistics
High Average Low
1989.59 % 160.4 % -100 %
(Sep 30 2023)   (Mar 31 2015)
Revenue first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #37
Healthcare Sector #59
Overall #158
Revenue Y/Y Growth Statistics
High Average Low
1989.59 % 160.4 % -100 %
(Sep 30 2023)   (Mar 31 2015)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Vbi Vaccines Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
936.29 % 66.95 % -100 %
(Dec 31 2018)  


VBIV's I. Quarter Q/Q Revenue Comment
Vbi Vaccines Inc achieved in the I. Quarter 2024 below company average Revenue jump of 42.82% quarter on quarter, to $ 1.21 millions.

Within Major Pharmaceutical Preparations industry 31 other companies have achieved higher Revenue quarter on quarter growth. While Vbi Vaccines Inc's Revenue growth quarter on quarter, overall rank is 255.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #32
Healthcare Sector #59
Overall #255
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #32
Healthcare Sector #59
Overall #255
Revenue Q/Q Growth Statistics
High Average Low
936.29 % 66.95 % -100 %
(Dec 31 2018)  


VBIV's I. Quarter Q/Q Revenue Comment
Vbi Vaccines Inc achieved in the I. Quarter 2024 below company average Revenue jump of 42.82% quarter on quarter, to $ 1.21 millions.

Within Major Pharmaceutical Preparations industry 31 other companies have achieved higher Revenue quarter on quarter growth. While Vbi Vaccines Inc's Revenue growth quarter on quarter, overall rank is 255.


Vbi Vaccines Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Mar 31 2023)
Cumulative Revenue 12 Months Ending $ 9.41 $ 8.68 $ 8.12 $ 1.82 $ 1.44
Y / Y Revenue Growth (TTM) 553.09 % 702.4 % 833.56 % 175 % 216.01 %
Year on Year Revenue Growth Overall Ranking # 112 # 0 # 741 # 3022 # 2966
Seqeuential Revenue Change (TTM) 8.4 % 6.89 % 347.49 % 25.95 % 33.18 %
Seq. Revenue Growth (TTM) Overall Ranking # 380 # 0 # 559 # 479 # 2864


Cumulative Revenue growth Comment
Assuming the Vbi Vaccines Inc's fiscal year would have ended in Mar 31 2024, Vbi Vaccines Inc would have reprted above average annual Revenue surge of 553.09% year on year, of $ 9 millions.
This marks a slow-down of the companys growth trends and from the 702.4% surge in Dec 31 2023.

Within the Healthcare sector 33 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 112.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 63
Healthcare Sector # 34
Overall # 112

Revenue TTM Y/Y Growth Statistics
High Average Low
833.56 %
 142.49 %
-66.04 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 63
Sector # 118
S&P 500 # 380
Cumulative Revenue growth Comment
Assuming the Vbi Vaccines Inc's fiscal year would have ended in Mar 31 2024, Vbi Vaccines Inc would have reprted above average annual Revenue surge of 553.09% year on year, of $ 9 millions.
This marks a slow-down of the companys growth trends and from the 702.4% surge in Dec 31 2023.

Within the Healthcare sector 33 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 112.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 63
Healthcare Sector # 34
Overall # 112

Revenue TTM Y/Y Growth Statistics
High Average Low
833.56 %
142.49 %
-66.04 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 63
Sector # 118
S&P 500 # 380




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
VBIV's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Mar 31 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2024
Bioadaptives Inc 255.27%$ 255.273 millions
Xoma Royalty Corporation240.96%$ 240.961 millions
Akili Inc 238.94%$ 238.938 millions
Plus Therapeutics Inc 231.42%$ 231.423 millions
Vaxart Inc 223.11%$ 223.111 millions
Sensus Healthcare Inc 212.33%$ 212.332 millions
Siga Technologies Inc205.54%$ 205.536 millions
Scpharmaceuticals Inc 195.78%$ 195.783 millions
Neuroone Medical Technologies Corp195.45%$ 195.445 millions
Bespoke Extracts Inc192.56%$ 192.563 millions
Bolt Biotherapeutics Inc 188.83%$ 188.828 millions
Ascendis Pharma A188.83%$ 188.826 millions
Bioxcel Therapeutics Inc 182.52%$ 182.524 millions
Oncternal Therapeutics Inc 180.30%$ 180.296 millions
Streamex Corp 180.00%$ 180.000 millions
Cg Oncology Inc 172.68%$ 172.680 millions
Poseida Therapeutics Inc 172.09%$ 172.087 millions
Innovative Eyewear Inc 164.61%$ 164.607 millions
Legend Biotech Corporation158.67%$ 158.672 millions
Nexalin Technology Inc 157.09%$ 157.095 millions
Vbi Vaccines Inc150.31%$ 150.309 millions
Sage Therapeutics Inc 139.89%$ 139.891 millions
Coherus Oncology inc 137.58%$ 137.585 millions
Docgo Inc 136.48%$ 136.484 millions
Entrada Therapeutics Inc 134.05%$ 134.046 millions
Transmedics Group Inc 133.07%$ 133.070 millions
Abeona Therapeutics Inc 131.59%$ 131.593 millions
Intellia Therapeutics Inc 129.53%$ 129.534 millions
Ocugen Inc 128.89%$ 128.894 millions
Rhythm Pharmaceuticals Inc 126.41%$ 126.410 millions


About Vbi Vaccines Inc Revenue Growth Rates (VBIV), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Vbi Vaccines Inc bc (CIK 764195).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001493152-24-019796
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Vbi Vaccines Inc bc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.